Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance

J Proteome Res. 2011 Oct 7;10(10):4567-78. doi: 10.1021/pr2004117. Epub 2011 Sep 21.

Abstract

A label-free quantitative variation of the recently developed data-independent shotgun proteomic method precursor acquisition independent from ion count (PAcIFIC) was used to identify novel proteins implicated in cancer progression and resistance. Specifically, this screen identified the pro-metastatic protein anterior gradient 2 (AGR2) as significantly up-regulated in tamoxifen-treated cells. Highlighting the need for direct proteome profiling methods like PAcIFIC, neither data-dependent gas-phase fractionation nor a transcriptomic screen detected AGR2 protein/transcript at significantly up-regulated levels. Further cell-based experiments using human cancer cell lines and in vivo xenografts confirmed the PAcIFIC hypothesis that AGR2 is up-regulated in MCF-7 cells post tamoxifen treatment and that it is implicated in drug resistance mediation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Hormonal / pharmacology
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mice
  • Mice, Nude
  • Models, Chemical
  • Mucoproteins
  • Neoplasm Transplantation
  • Oncogene Proteins
  • Proteins / metabolism
  • Proteomics / methods*
  • Tamoxifen / pharmacology*

Substances

  • AGR2 protein, human
  • Antineoplastic Agents, Hormonal
  • Mucoproteins
  • Oncogene Proteins
  • Proteins
  • Tamoxifen